CHA Biotech's subsidiary CHA Vaccine announced on the 8th that it will jointly develop messenger ribonucleic acid (mRNA) vaccines and therapeutics with SML Biopharm. mRNA serves as a 'messenger' that transmits part of the DNA information to ribosomes, a cellular organelle, to synthesize proteins. Utilizing mRNA technology can prevent infectious diseases and develop various therapeutics.
CHA Vaccine and SML Biopharm have signed a comprehensive business agreement to this end. The two companies will conduct candidate substance discovery, formulation, and clinical trials. SML Biopharm will provide mRNA sequence design, optimization technologies for the key components UTR and Poly(A), and a high-efficiency, low-toxicity lipid nanoparticle (LNP) delivery platform. CHA Vaccine will discover vaccine antigens, validate efficacy, and lead clinical trials.
Han Seong-il, CEO of CHA Vaccine, noted, "We will extend the application of mRNA beyond infectious disease vaccines to therapeutics." Nam Jae-hwan, CEO of SML Biopharm, said, "We will develop a next-generation pipeline that has global competitiveness."